New Methods of Endocrine Management of Prostatic Cancer

    January 1987 in “ ˜The œJournal of urology/˜The œjournal of urology ”
    Joseph A. Smith
    TLDR New hormonal therapies can help treat advanced prostate cancer but may cause testicular issues.
    The document reviewed new methods of endocrine management for prostatic cancer as of 1987. It discussed various hormonal therapies and their effectiveness in treating advanced stages of the disease. The review highlighted the use of nonsteroidal antiandrogens, luteinizing hormone-releasing hormone (LHRH) agonists, and other androgen withdrawal therapies. The findings suggested that these treatments could induce regression in prostate cancer, although long-term use might lead to testicular impairment. The review provided a comprehensive overview of the available endocrine treatment options and their potential impacts on patients.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 70 results

      community Fluridil (Eucapil) seems like a great option?

      in Treatment  2 upvotes 1 week ago
      The user stopped using finasteride due to side effects and is considering Fluridil (Eucapil) as an alternative for hair loss treatment. They are exploring other options like RU58841 and are interested in the experiences of others with Fluridil, noting its good safety profile despite the cost.

      community DHT blocking ingredients

      in Treatment  6 upvotes 4 years ago
      The conversation discusses DHT blocking treatments for hair loss, specifically mentioning Minoxidil, Finasteride, and organic flaxseed oil containing omega-3 fatty acids. It highlights skepticism about alternative treatments and emphasizes the proven effectiveness of Finasteride and Dutasteride.

      community Binding affinity of pyrilutamide!

      in Update  171 upvotes 3 years ago
      Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

    Related Research

    1 / 1 results